Journal of Anesthesia Practice

The Journal of Anaesthesia Practice published an article on September 28, 2020, regarding some of the latest concerns and solutions surrounding anesthesia delivery during the COVID pandemic.

Because healthcare workers performing aerosol-generating procedures are more susceptible to acquiring acute respiratory infections and because postoperative pulmonary complication rates are higher in COVID patients, the American Society of Regional Anesthesia and Pain Medicine (ASRA) and the European Society of Regional Anaesthesia and Pain Therapy (ESRA) advise using regional anesthesia rather than general anesthesia wherever possible.

Regional Anesthesia Benefits to the Patient Include

  • Improved postoperative pain management
  • Lower incidences of postoperative nausea/vomiting
  • Earlier mobilization
  • Reduced opioid abuse

Regional Anesthesia Benefits to the Healthcare Team Include

  • Preserving key drugs during the pandemic
  • Reduction in aerosol-generated infections
  • Less intense postoperative pain management
  • Earlier discharge

Precautions Healthcare Workers Can Take

  • Performing procedures in negative pressure rooms
  • Using a surgical mask on the patient rather than nasal prongs
  • Keeping supplemental oxygen flow to a minimum
  • Limiting the number of staff present during the procedure

The article explains that having only essential staff present can be accomplished with the use of SAFIRA™ from Medovate, a device that makes regional anesthesia a one operator procedure, giving anesthesiologists or nurse anesthetists control of the whole procedure.

Click here to read the complete article.


SAFIRA™ from Medovate gives anesthesiologists the tools to confidently take control of regional anesthesia injection. SAFIRA™ has a built-in system to help prevent injection at pressures above 20psi, which helps reduce the risk of significant or transient nerve damage.

In addition, SAFIRA™ makes regional anesthesia a one operator procedure, giving anesthesiologists control of the whole procedure.

SAFIRA™ promotes better outcomes for patients, saves time and resources, and can help reduce costs of reintervention or lawsuits.

To learn more about SAFIRA™ from Medovate, call 888-891-1200 or email us to be connected to your local sales representative.

MED Alliance Group is an ISO 13485 certified medical device distributor and has been dedicated to meeting the needs of our clinical customers and manufacturing partners since 1998. We specialize in the sales, marketing, importation, logistics and distribution of innovative, high-quality and cost-effective products found in anesthesia and respiratory, blood and transfusion therapy, EMS and emergency room, interventional radiology and cath lab, iv and vascular, as well as NICU and PICU.

Please follow us on LinkedIn, Facebook and Twitter for MED Alliance product updates.

SAFIRA product photo